Fresenius Medical Care AG & Co. KGaA

XETRA FME.DE

Fresenius Medical Care AG & Co. KGaA Price to Sales Ratio (P/S) on January 14, 2025: 0.61

Fresenius Medical Care AG & Co. KGaA Price to Sales Ratio (P/S) is 0.61 on January 14, 2025, a 12.09% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Fresenius Medical Care AG & Co. KGaA 52-week high Price to Sales Ratio (P/S) is 0.66 on December 09, 2024, which is 8.36% above the current Price to Sales Ratio (P/S).
  • Fresenius Medical Care AG & Co. KGaA 52-week low Price to Sales Ratio (P/S) is 0.49 on August 12, 2024, which is -18.90% below the current Price to Sales Ratio (P/S).
  • Fresenius Medical Care AG & Co. KGaA average Price to Sales Ratio (P/S) for the last 52 weeks is 0.56.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
XETRA: FME.DE

Fresenius Medical Care AG & Co. KGaA

CEO Ms. Helen Giza
IPO Date July 22, 1998
Location Germany
Headquarters Else-KrOener Strasse 1
Employees 113,079
Sector Health Care
Industries
Description

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Similar companies

MRK.DE

MERCK Kommanditgesellschaft auf Aktien

USD 145.16

0.75%

DB1.DE

Deutsche Börse AG

USD 235.70

1.85%

FRE.DE

Fresenius SE & Co. KGaA

USD 35.88

1.39%

BEI.DE

Beiersdorf Aktiengesellschaft

USD 127.49

-1.31%

StockViz Staff

January 15, 2025

Any question? Send us an email